The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors
Official Title: A Phase 1, Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) as a Single Agent and in Combination With Approved Immune Checkpoint Inhibitors in Patients With Relapsed/ Refractory Solid Tumors
Study ID: NCT05108623
Brief Summary: This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed/refractory (r/r) solid tumors, as well as define the recommended phase II dose in solid tumors. This Phase 1 study will also explore the safety, tolerability, and preliminary clinical activity of agenT-797 in combination with approved immune checkpoint inhibitors (ICIs), including pembrolizumab and nivolumab, in participants with r/r solid tumors.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Southern California, Los Angeles, California, United States
University of Colorado, Aurora, Colorado, United States
Norton Cancer Health, Louisville, Kentucky, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
University of Cincinnati Cancer Center, Cincinnati, Ohio, United States
Providence Portland Medical Center, Portland, Oregon, United States
LifeSpan - Rhode Island Hospital, Providence, Rhode Island, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Name: Medical Director
Affiliation: MiNK Therapeutics
Role: STUDY_DIRECTOR